Edwards Lifesciences Equity Securities Without Readily Determinable Fair Value - Cumulative Upward Adjustments remained flat by 0.0% to $9.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.1%, from $9.30M to $9.40M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful investment performance and growth in the value of private holdings, while a decrease suggests stagnation or lack of appreciation.
Represents the cumulative total of upward valuation adjustments applied to equity investments that lack a readily determ...
Standard metric for banks and investment firms that hold significant non-marketable equity stakes.
equity_securities_no_fv_upward_adj| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $8.80M | $8.80M | $9.30M | $9.30M | $9.30M | $9.40M | $9.40M |
| QoQ Change | — | +0.0% | +5.7% | +0.0% | +0.0% | +1.1% | +0.0% |
| YoY Change | — | — | — | +5.7% | +5.7% | +1.1% | +1.1% |